Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, William T. Clarke, Niels Vande Casteele, Katharine A. Germansky, Joseph D. Feuerstein, Gil Melmed, Corey A. Siegel, Peter M. Irving, Adam S. Cheifetz
Topics & Concepts
AdalimumabInfliximabMedicineTherapeutic drug monitoringInflammatory bowel diseaseDrugInternal medicineTumor necrosis factor alphaTumor necrosis factor αInflammatory Bowel DiseasesGastroenterologyPharmacologyDiseaseInflammatory Bowel DiseasePharmaceutical studies and practicesBiosimilars and Bioanalytical Methods